Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit (Sarah Merians Photography for Endpoints News)
Biogen CEO sees Alzheimer's drug on right path despite tiny sales, will keep biosimilars business
A year after unveiling its “Fit for Growth” restructuring effort, Biogen is on track to reverse multiple years of declining revenues, CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
